How to Get Zetia (Ezetimibe) in North Dakota

What Ezetimibe Does and Why North Dakota Clinicians Prescribe It

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 54% and lowering LDL-C by 18 to 25% as monotherapy. [1] North Dakota clinicians prescribe it most often as an add-on to statin therapy when LDL-C targets are not met, or as a statin alternative when a patient cannot tolerate higher statin doses.

The IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 is the landmark evidence base. Patients with recent acute coronary syndrome already on simvastatin were randomized to add ezetimibe 10 mg or placebo. The combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-alone arm. [2] The primary composite cardiovascular endpoint was reduced from 34.7% to 32.7%, a statistically significant absolute risk reduction of 2.0 percentage points (HR 0.936; 95% CI 0.89 to 0.99; P<0.001) over a median 6-year follow-up. [2]

The ACC/AHA 2018 Cholesterol Guideline formally recommends ezetimibe as the first non-statin add-on agent for patients with atherosclerotic cardiovascular disease (ASCVD) whose LDL-C remains above 70 mg/dL despite maximally tolerated statin therapy. [3] The guideline states: "In patients with clinical ASCVD in whom LDL-C remains above 70 mg/dL on maximally tolerated statin therapy, ezetimibe is reasonable as a next step." [3]

The FDA approved ezetimibe (brand name Zetia) for use as an adjunct to diet to reduce elevated LDL-C, and the current prescribing information is available through the FDA's drug database. [4] The drug carries no black-box warning. Liver-enzyme elevation occurs at rates similar to placebo in controlled trials. [4]

The Step-by-Step Process to Get Zetia in North Dakota

Getting a Zetia prescription in North Dakota requires four sequential steps: a qualifying medical consultation, a fasting lipid panel, a written or electronic prescription, and pharmacy dispensing. Each step is straightforward and can now be completed without leaving your home if you use a licensed telehealth provider.

Step 1. Schedule a consultation. Book either an in-person appointment with a North Dakota-licensed physician, NP, or PA, or schedule a synchronous telehealth video visit. North Dakota Century Code Chapter 43-17 and the North Dakota Board of Medicine's telemedicine policy permit prescribing via audio-video telehealth after a proper patient-provider relationship is established. [5]

Step 2. Complete a fasting lipid panel. A lipid panel drawn after a 9 to 12-hour fast is required to establish a baseline LDL-C, HDL-C, total cholesterol, and triglycerides. If ezetimibe will be co-prescribed with a statin, your provider will also order a hepatic function panel (ALT, AST, bilirubin) per FDA labeling. [4] Most telehealth platforms send lab orders electronically to LabCorp or Quest Diagnostics, both of which have patient service centers in Fargo, Bismarck, Grand Forks, and Minot.

Step 3. Attend the prescribing visit. Your provider reviews your labs, cardiovascular risk score, current medications, and personal health history. If ezetimibe is appropriate, an electronic prescription (e-Rx) is transmitted directly to your preferred pharmacy.

Step 4. Pick up or receive your medication. Most North Dakota retail pharmacies stock generic ezetimibe 10 mg. Mail-order pharmacies can ship to any North Dakota address, typically arriving within 2 to 4 business days of prescription transmittal.

Telehealth Prescribing for Zetia in North Dakota

North Dakota fully permits telehealth prescribing for non-controlled medications including ezetimibe. Telehealth is particularly valuable in North Dakota because the state has the fourth-lowest population density in the contiguous United States, and many residents live more than 60 miles from the nearest cardiologist or lipidologist.

North Dakota's telehealth statute (N.D.C.C. 26.1-36-09.20) requires that a valid patient-provider relationship be established before prescribing, which a synchronous video or audio-video visit satisfies. [5] A prescription written via telehealth carries the same legal weight as one written in a physical office. Providers licensed in any state may prescribe to North Dakota residents if they hold an active North Dakota license or a qualifying Interstate Medical Licensure Compact (IMLC) license. [6]

Telehealth visits for lipid management typically take 15 to 30 minutes. You will need to share recent lab results (within 90 days is generally acceptable) or agree to complete a new lipid panel before the prescription is finalized. Several national telehealth platforms and HealthRX's own licensed North Dakota providers can complete this visit. After the visit, the e-Rx reaches your pharmacy within minutes.

The American Heart Association has noted that telehealth significantly expands access to cardiovascular risk-factor management, particularly in rural states. [7] A 2022 analysis published in JAMA Network Open found that patients who received telehealth-based statin or lipid-lowering therapy management showed comparable LDL-C reductions to those managed in-person. [8]

Required Labs Before Starting Zetia in North Dakota

Two lab tests are standard before starting ezetimibe: a fasting lipid panel and, when combining with a statin, a liver function panel.

A fasting lipid panel measures LDL-C, HDL-C, total cholesterol, and triglycerides. [9] Your provider uses these values alongside your 10-year ASCVD risk score (calculated with the Pooled Cohort Equations) to determine whether ezetimibe is appropriate and to set a target LDL-C reduction. [3] The ACC/AHA guideline identifies four groups most likely to benefit from lipid-lowering therapy, and patients in those groups with LDL-C at or above 70 mg/dL despite statin therapy are prime candidates for ezetimibe. [3]

Liver function tests (ALT and AST) are recommended at baseline when co-prescribing ezetimibe with a statin because statins carry a low but real risk of hepatotoxicity, and a baseline reading is needed to interpret any future elevation. [4] Ezetimibe alone does not require routine liver monitoring beyond baseline per current FDA labeling. [4]

A TSH (thyroid-stimulating hormone) test is often ordered at the same visit because hypothyroidism is a secondary cause of elevated LDL-C; treating an undiagnosed thyroid disorder can normalize lipids without adding a cholesterol drug. [10] Your North Dakota provider will determine whether additional metabolic labs (fasting glucose, HbA1c, comprehensive metabolic panel) are needed based on your individual cardiovascular risk profile.

Who Can Prescribe Zetia in North Dakota

In North Dakota, any licensed prescriber with the legal authority to write non-controlled prescriptions can prescribe ezetimibe. That includes physicians (MD, DO), nurse practitioners (NP), physician assistants (PA), and clinical pharmacist practitioners operating under a collaborative practice agreement. [11]

Nurse practitioners in North Dakota hold full practice authority under N.D.C.C. 43-12.1, meaning they can prescribe without physician oversight. [11] This is relevant for telehealth because many national platforms deploy NPs as primary prescribers. Physician assistants prescribe under a supervision agreement but can independently transmit an e-Rx in most practice settings. [12]

Cardiologists, internists, and family medicine physicians all routinely prescribe ezetimibe. If your cardiovascular risk is complex (recent MI, familial hypercholesterolemia, PCSK9 inhibitor candidacy), a referral to a North Dakota lipidologist or preventive cardiologist at Sanford Health, CHI St. Alexius, or Altru Health System may add value.

Prior Authorization Requirements for Zetia in North Dakota

Most North Dakota commercial insurance plans require prior authorization (PA) for brand-name Zetia. Generic ezetimibe is often covered without prior authorization at a lower tier, making it the practical starting point for most patients.

For brand Zetia, a typical prior authorization from a North Dakota commercial plan will ask for: documented LDL-C values on the current lipid panel, evidence of a statin trial at maximally tolerated dose for at least 4 to 8 weeks, and documentation of the patient's ASCVD risk category or diagnosis. [13] Some plans also require documentation of statin intolerance if ezetimibe is being used as monotherapy.

North Dakota Medicaid does not cover ezetimibe for the hyperlipidemia adjunct indication as of the date of this article's last review. Patients on Medicaid may appeal this decision with clinical documentation from their provider, or they may use manufacturer patient assistance programs. Merck's patient assistance program (Merck Helps) and the manufacturer of generic ezetimibe both offer copay reduction programs for eligible patients. [14]

The appeals process for a denied prior authorization in North Dakota is governed by N.D.C.C. 26.1-04-15, which requires insurers to provide written notice of denial and allow an expedited appeal for urgent clinical situations. [13] Your provider's office can submit a peer-to-peer appeal, which reverses denials in a significant proportion of cases when IMPROVE-IT-level evidence is cited directly. [2]

Pharmacy Options for Filling Zetia in North Dakota

Generic ezetimibe 10 mg is stocked at virtually every retail pharmacy chain operating in North Dakota, including Walmart Pharmacy, Walgreens, Rite Aid, and independent pharmacies in smaller communities. The GoodRx cash price for 30 tablets of generic ezetimibe 10 mg averages $15 to $25 at North Dakota pharmacies as of mid-2025, well below the brand Zetia retail price of approximately $300 per month. [14]

Mail-order pharmacies licensed in North Dakota can also dispense ezetimibe with a valid e-Rx. North Dakota Century Code Chapter 43-15 licenses out-of-state mail-order pharmacies that register with the North Dakota Board of Pharmacy. [15] This means patients in Williston, Dickinson, or any rural community can have a 90-day supply shipped to their door, often at a lower per-tablet cost than retail.

503A compounding pharmacies licensed in North Dakota may also prepare ezetimibe-containing formulations for patients with documented medical need (for example, a patient who cannot swallow standard tablets and requires a liquid suspension). [16] The FDA's current policy on 503A compounding clarifies that individual patient prescriptions are required; bulk compounding for office stock is not permitted under 503A. [16]

The North Dakota Board of Pharmacy maintains a public directory of all licensed pharmacies, including compounding and mail-order facilities. [15] Verify your pharmacy's license status before transferring a prescription.

Transferring an Existing Zetia Prescription to North Dakota

Transferring an existing Zetia or generic ezetimibe prescription to a North Dakota pharmacy is straightforward under federal and state law.

Federal law (21 U.S.C. 353) and North Dakota pharmacy rules permit a one-time transfer of a non-controlled prescription between pharmacies in different states. [15] Contact the receiving North Dakota pharmacy with the name and phone number of your previous pharmacy; the pharmacist-to-pharmacist transfer can typically be completed within a few hours. If your prescription has no remaining refills, the receiving pharmacy will contact your original prescriber for a new e-Rx.

Telehealth patients who relocate to North Dakota mid-supply should contact their telehealth provider to confirm that the provider holds an active North Dakota prescribing license or an IMLC license covering North Dakota. If not, a new prescribing relationship with a North Dakota-licensed provider will be needed before a new prescription can be issued.

Ezetimibe Safety, Side Effects, and Monitoring

Ezetimibe has a favorable safety profile across more than 20 years of post-marketing data. The most commonly reported adverse effects are upper respiratory infections (4.3%), diarrhea (4.1%), and arthralgia (3.0%) based on the FDA-approved prescribing information, rates that are only marginally above placebo. [4]

Myopathy risk is low with ezetimibe alone but warrants monitoring when combined with a statin, particularly high-dose simvastatin. [4] The FDA issued a drug-interaction warning in 2011 specific to simvastatin 80 mg doses; that combination is now generally avoided, and most guidelines recommend substituting rosuvastatin or atorvastatin when high-intensity statin therapy is needed alongside ezetimibe. [17]

A meta-analysis of 27 randomized controlled trials (N=182,667) published in the Lancet in 2010 quantified that each 1 mmol/L (roughly 38.7 mg/dL) reduction in LDL-C reduces major vascular events by approximately 21%, regardless of the drug class used to achieve it. [18] Ezetimibe-mediated LDL-C reduction produces proportional risk reduction consistent with this relationship, as subsequently confirmed by IMPROVE-IT. [2]

Routine follow-up for patients on ezetimibe includes a repeat fasting lipid panel 4 to 12 weeks after starting therapy to assess LDL-C response, with annual monitoring thereafter. [3] Patients who experience unexplained muscle pain, weakness, or dark urine should contact their provider promptly and hold the medication pending evaluation.

Cost and Insurance Coverage Summary for North Dakota Patients

Cost is a top concern for patients in North Dakota, where median household incomes in many rural counties fall below the state average of $65,315 (2023 American Community Survey data). Generic ezetimibe addresses cost effectively.

At most North Dakota pharmacies, a 30-day supply of generic ezetimibe costs $15 to $25 cash. A 90-day mail-order supply often runs $35 to $60, dropping the per-day cost to under $0.70. [14] Most commercial insurance plans cover generic ezetimibe at Tier 1 or Tier 2 with no prior authorization, resulting in copays of $0 to $15 per month for insured patients.

Brand-name Zetia is classified Tier 3 or Tier 4 on most North Dakota formularies, with a prior authorization requirement and copays ranging from $50 to $150 per month even after approval. Given that generic ezetimibe is pharmaceutically equivalent to brand Zetia (same active ingredient, same 10 mg dose, same bioavailability established through FDA-required BE studies [4]), there is no clinical rationale for insisting on brand when the generic is available.

Medicare Part D plans operating in North Dakota include generic ezetimibe on formulary; coverage tier and copay vary by plan. Patients in the catastrophic coverage phase or Low-Income Subsidy may pay $0 to $3.90 per fill under current CMS benchmarks. [19]

Clinical Evidence Summary: Why Ezetimibe Works

The mechanistic and outcomes evidence for ezetimibe is extensive. Three bodies of data are most relevant to a North Dakota prescribing decision.

First, mechanistic: ezetimibe reduces fractional cholesterol absorption by approximately 54%, demonstrated in a radiolabeled cholesterol absorption study, with a corresponding upregulation of hepatic LDL receptors that amplifies LDL-C lowering. [1] This mechanism is additive with statins because statins reduce hepatic cholesterol synthesis while ezetimibe reduces intestinal absorption.

Second, outcomes: IMPROVE-IT (N=18,144) remains the only large cardiovascular outcomes trial specifically powered to evaluate the incremental benefit of adding a non-statin agent to statin therapy. [2] At 7-year follow-up, the number needed to treat to prevent one major cardiovascular event was 50, a figure comparable to the NNT for statin therapy in secondary prevention. [2]

Third, safety across populations: A Cochrane review of ezetimibe for prevention of cardiovascular events (last updated 2020, 26 trials, N=23,499) found no increase in cancer, myopathy, or hepatotoxicity compared with placebo over follow-up periods of up to 7 years. [20] The review concluded that ezetimibe reduces the risk of non-fatal MI and coronary revascularization.

The ACC/AHA guideline notes that ezetimibe is the preferred non-statin agent before PCSK9 inhibitors because of its oral route, well-established safety record, low cost, and Level of Evidence A recommendation for secondary prevention. [3]